Notice of Proposed Sale · 144
Oric Pharmaceuticals, Inc.
ORICNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Oric Pharmaceuticals, Inc.
- Issuer CIK
- 0001796280
- SEC file number
- 001-39269
- Phone
- 6503885600
- Person for whose account securities are to be sold
- Richard A, Heyman
- Relationships to issuer
- Director
- Street
- 240 E. Grand Ave
- Street (continued)
- 2nd Floor
- City
- San Francisco
- State / country code
- CA
- Postal code
- 94080
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 6,400 | 76,800 | 103,517,562 | 07/06/2026 | Nasdaq | J.P. Morgan Securities LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- J.P. Morgan Securities LLC
- Street
- 270 Park Avenue
- Street (continued)
- 10th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10017
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/31/2015 | Stock Option Exercise | Issuer | 6,400 | N | 07/31/2015 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The shares filed today will be sold by RAHD Capital, LLC, Richard T. Kuehnle as Manager.
Notice signature
- Notice date
- 07/06/2026
- Signed
- /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Richard A. Heyman.
- Plan adoption dates
- 09/26/2025
Company context
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.